Valneva Receives Positive Opinion for its COVID-19 Vaccine Candidate in Europe | Photo credits: Valneva
June 23 (Reuters) – Valneva announced on Thursday that it had received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), for marketing authorization in Europe for its vaccine candidate. inactivated against COVID-19.
The authorization concerns use of the inactivated whole virus vaccine candidate as a primary vaccination in adults aged 18 to 55, the laboratory said in a press release.
The European Commission must soon decide on this recommendation, which could lead to an order for vaccines.
“We hope that the European Commission and its member states will recognize the potential benefits of an inactivated vaccine and place a sizeable order,” chief executive Thomas Lingelbach said in the statement. (Writing by Kate Entringer, editing by Sophie Louet)